Graphite Bio Inc Stock

$31.93

5.36% yesterday

Nasdaq, Jun 06, 09:48 pm CET

ISIN

US38870X1046

Symbol

LENZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Graphite Bio Inc Stock price

$31.96

-55.60 63.50% 5Y

Nasdaq, Closing price Fri, Jun 06 2025

+1.66 5.48%

ISIN

US38870X1046

Symbol

LENZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$899.55m
Enterprise Value	$705.57m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	4.58
Dividend yield	0.00%
Last dividend (FY24)	$7.21
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-59.45m
Free Cash Flow (TTM) Free Cash Flow	$-52.08m
Cash position	$193.98m
EPS (TTM) EPS	$-1.73
P/E forward	negative
P/S forward	129.63
EV/Sales forward	101.68
Short interest	22.47%

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Get Started for Free Today

Graphite Bio Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Graphite Bio Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Graphite Bio Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Graphite Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	34 34	12% 12% -
- Research and Development Expense	25 25	5% 5% -
EBITDA	-59 -59	52% 52% -
- Depreciation and Amortization	0.09 0.09	95% 95% -
EBIT (Operating Income) EBIT	-59 -59	52% 52% -
Net Profit	-48 -48	59% 59% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Graphite Bio Inc Stock News

Neutral

Seeking Alpha

●

29 days ago

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Pawan Patel - Bank of America Yigal Nochomovitz - Citi La...

Neutral

GlobeNewsWire

●

29 days ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia.

Neutral

GlobeNewsWire

●

about one month ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025

More Graphite Bio Inc News

Company Profile

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Evert Schimmelpennink
Founded	2017
Website	lenz-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now